Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Published byAdi Irawan Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase."— Presentation transcript:

1 Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)  Andrew Blauvelt, MD, MBA, Melinda Gooderham, MD, MSc, Lars Iversen, MD, DMSc, Susan Ball, PhD, Lu Zhang, MS, Noah O. Agada, MD, Kristian Reich, MD  Journal of the American Academy of Dermatology  Volume 77, Issue 5, Pages (November 2017) DOI: /j.jaad Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Time course of PASI response rates through 108 weeks of treatment with the recommended ixekizumab dosing regimen. PASI 75 (A), PASI 90 (B), and PASI 100 (C) response rates at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation; MI, modified multiple imputation; PASI 75/90/100, 75/90/100 percent improvement from baseline in the Psoriasis Area and Severity Index. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Time course of sPGA response rates through 108 weeks of treatment with the recommended ixekizumab dosing regimen. sPGA (0,1) (A) and sPGA (0) (B) response rates at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation; mMI, modified multiple imputation; sPGA (0,1) or (0), static Physician's Global Assessment score of 0 or 1 (0,1) or 0 (0). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Fingernail, scalp, and nonpustular palmoplantar psoriasis clearance rates at 108 weeks with recommended ixekizumab dosing regimen. A, NAPSI = 0 response rate at each postbaseline visit for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Only fingernail psoriasis was assessed in UNCOVER-3. B, PSSI = 0 and PPASI 100 response rate at 108 weeks for the ixekizumab every 2 weeks (from weeks 0 to 12) and then ixekizumab every 4 weeks (from weeks 13 to 108) dosing regimen. Response rates are determined for patients with baseline fingernail, scalp, or nonpustular palmoplantar psoriasis. The as-observed sample size for each measure is provided for the 108-week visit. Error bars represent 95% confidence intervals. MI, Multiple imputation, mMI, modified nonresponder imputation; NAPSI = 0, Nail Psoriasis Severity Index score of 0; PPASI 100, 100% improvement from baseline in the Palmoplantar Psoriasis Area and Severity Index; PSSI = 0, Psoriasis Scalp Severity Index score of 0. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Long-term efficacy response rates for the recommended dosing regimen excluding patient visits with increased dose frequency. PASI 75 (A) and sPGA (0,1) (B) response rates for each visit weeks for the ixekizumab every 2 weeks (for weeks 0-12) and then ixekizumab every 4 weeks (for weeks ) dosing regimen including (+ IXE Q2W) and excluding (– IXE Q2W) data from visits with patients receiving ixekizumab every 2 weeks. The as-observed sample size is provided for the 108-week visit. Error bars represent 95% confidence intervals. IXE, Ixekizumab; MI, multiple imputation; mMI, modified multiple imputation; PASI 75, 75% improvement from baseline in the Psoriasis Area and Severity Index; Q2W, every 2 weeks; sPGA (0,1), static Physician's Global Assessment score of 0 or 1. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Remission and time of resolution of nail psoriasis during infliximab therapy  Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Dermatology physician extenders: A new risk factor?

Dermatology physician extenders: A new risk factor?
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Similar presentations

Ads by Google